0

Antal anställda

0

Antal patent och patentansökningar

0

Antal biosimilarkandidater under utveckling

Kapitalmarknadsdag 17 maj, 2021


Hemma hos Xbrane Biopharma


Pressmeddelanden

16 May 2024

Xbrane Biopharma releases Interim Report for January-March 2024

13 May 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024

10 May 2024

Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US

02 May 2024

Announcement from Xbrane Biopharma’s annual general meeting

21 Apr 2024

Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate

02 Apr 2024

Notice of annual general meeting in Xbrane Biopharma AB

01 Apr 2024

Change of number of shares and votes in Xbrane

27 Mar 2024

XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023

19 Mar 2024

Xbrane resolves on a directed issue of shares to guarantors in connection with the completed rights issue